ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part two: treatment
Paediatric mycosis fungoides (MF) is characterized by early-stage disease, a strikingly indolent course and high rates of unusual variants. Despite these clinical peculiarities and the special treatment-related safety considerations in children and adolescents, detailed published data on treatments of paediatric MF are scarce, and management is currently based primarily on standard practice in adults. The aim of this work was to develop treatment recommendations specifically designed for MF in children and adolescents, on behalf of the three largest societies for cutaneous lymphomas, the International Society for Cutaneous Lymphomas (ISCL), the European Organisation for Research and Treatment of Cancer - Cutaneous Lymphoma Tumour Group (EORTC-CLTG), and the United States Cutaneous Lymphoma Consortium (USCLC). We developed this guideline through an international expert consensus process and in accordance with the EQUATOR Network's recommendations for guideline development. A modified Delphi process was conducted, using questionnaires covering treatment modalities that are recommended by international guidelines for adult MF. Two rounds of expert feedback were conducted, with an additional one hybrid consensus meeting. Therapeutic recommendations were formulated focusing mainly on early-stage disease. These recommendations take into account disease-specific parameters with therapeutic implications, including the specific stage of the disease, the type of lesion, and the presence of the folliculotropic variant, which is commonly observed in the paediatric age group. Patient-related factors, including safety concerns specific to this young age group, were also addressed. This ISCL/EORTC-CLTG/USCLC guideline provides up-to-date age-specific practical recommendations for the treatment of MF in children and adolescents.
Authors
- Rudolf Stadler (ORCID: https://orcid.org/0000-0003-2683-6028)
- Martine Bagot (ORCID: https://orcid.org/0000-0002-0400-1954)
- Amra Osmančević (ORCID: https://orcid.org/0000-0002-8227-8369)
- Chalid Assaf (ORCID: https://orcid.org/0000-0002-7898-9432)
- José Antônio Sanches (ORCID: https://orcid.org/0000-0002-5709-092X)
- Maria Luisa Sulis (ORCID: https://orcid.org/0000-0003-2110-0193)
- Jong Bin Park (ORCID: https://orcid.org/0000-0002-3547-421X)
- Madeleine Duvic (ORCID: https://orcid.org/0000-0002-8971-4565)
- Montserrat Molgó
- Jan P. Nicolay (ORCID: https://orcid.org/0000-0003-0220-0551)
- Arti Nanda (ORCID: https://orcid.org/0000-0002-1223-3181)
- Pablo Luis Ortiz-Romero (ORCID: https://orcid.org/0000-0003-2985-9639)
- Tim Niehues (ORCID: https://orcid.org/0000-0002-9945-8833)
- Francine M. Foss
- Emmilia Hodak (ORCID: https://orcid.org/0000-0002-1645-8038)
- Katalin Ferenczi (ORCID: https://orcid.org/0000-0001-8649-4504)
- Mark Jean Aan Koh (ORCID: https://orcid.org/0000-0002-4136-4105)
- Pietro Quaglino (ORCID: https://orcid.org/0000-0003-4185-9586)
- John A. Zic
- Evangelia Papadavid (ORCID: https://orcid.org/0000-0002-8634-102X)
- Emmanuella Guenova (ORCID: https://orcid.org/0000-0001-5478-8735)
- Julia Jane Scarisbrick (ORCID: https://orcid.org/0000-0002-8011-4408)
- Franz Trautinger (ORCID: https://orcid.org/0000-0001-8233-938X)
- Iris Wieser (ORCID: https://orcid.org/0000-0003-4714-838X)
- Dan Ben Amitai (ORCID: https://orcid.org/0000-0001-6390-1269)
- Maarten H. Vermeer (ORCID: https://orcid.org/0000-0002-5872-4613)
- Maxime Battistella (ORCID: https://orcid.org/0000-0002-7053-7431)
- Larisa J. Geskin (ORCID: https://orcid.org/0000-0001-7348-2571)
- Iris Amitay‐Laish
- Youn H. Kim (ORCID: https://orcid.org/0000-0003-2686-5873)
- Antonio Cozzio (ORCID: https://orcid.org/0000-0002-8299-1746)
Institutions
- Johannes Kepler University of Linz (AT)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Connecticut (US)
- Pontificia Universidad Católica de Chile (CL)
- Universidade de São Paulo (BR)
- National and Kapodistrian University of Athens (GR)
- University of St.Gallen (CH)
- Université Paris Cité (FR)
- Heidelberg University (DE)
- Paracelsus Medical University (AT)
- Columbia University Irving Medical Center (US)
- Leiden University Medical Center (NL)
- Rabin Medical Center (IL)
- Sahlgrenska University Hospital (SE)
- Saint Louis University Hospital (US)
- University Hospital Heidelberg (DE)
- Yale Cancer Center (US)
- University Medical Center (US)
- Research Institute Hospital 12 de Octubre (ES)
- MSH Medical School Hamburg – University of Applied Sciences and Medical University (DE)
- Region Västra Götaland (SE)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospital Universitario 12 De Octubre (ES)
- Helios Klinikum Krefeld (DE)
- Schneider Children's Medical Center (IL)
- KK Women's and Children's Hospital (SG)
- Universitätsklinikum St. Pölten (AT)
- NIHR Surgical Reconstruction and Microbiology Research Centre (GB)
- Hôpital Saint-Louis (FR)
- University Medical Centre Mannheim (DE)
- Institute for Molecular Medicine (US)
- Johannes Wesling Klinikum Minden (DE)
- Dermatology Research Center (US)
- University of Turin (IT)
- UConn Health (US)
- University of Gothenburg (SE)
- Vanderbilt University Medical Center (US)
- Kosin University (KR)
- Stanford University (US)
- University of Lausanne (CH)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1093/bjd/ljaf198
- Citations
- 1
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 2.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Celgene
- Cilag